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SUMMARY
Soluble Amyloid-β oligomers (Aβo) trigger Alzheimer’s disease (AD) pathophysiology and bind
with high affinity to Cellular Prion Protein (PrPC). At the post-synaptic density (PSD),
extracellular Aβo bound to lipid-anchored PrPC activates intracellular Fyn kinase to disrupt
synapses. Here, we screened transmembrane PSD proteins heterologously for the ability to couple
Aβo–PrPC with Fyn. Only co-expression of the metabotropic glutamate receptor, mGluR5,
allowed PrPC-bound Aβo to activate Fyn. PrPC and mGluR5 interact physically, and cytoplasmic
Fyn forms a complex with mGluR5. Aβo–PrPC generates mGluR5-mediated increases of
intracellular calcium in Xenopus oocytes and in neurons, and the later is also driven by human AD
brain extracts. In addition, signaling by Aβo–PrPC–mGluR5 complexes mediates eEF2
phosphorylation and dendritic spine loss. For mice expressing familial AD transgenes, mGluR5
antagonism reverses deficits in learning, memory and synapse density. Thus, Aβo–PrPC
complexes at the neuronal surface activate mGluR5 to disrupt neuronal function.
INTRODUCTION
Alzheimer’s disease (AD) has a distinct pathology with plaques of amyloid-β (Aβ) and
tangles of hyperphosphorylated tau. Rare autosomal dominant AD cases with mutations of
Amyloid-β Precursor Protein (APP) or Presenilin (PS1 or PS2) provide proof that Aβ
pathways can trigger AD (reviewed in (Holtzman et al., 2011)). Other APP mutations reduce
AD risk (Jonsson et al., 2012). Biomarker studies of late onset AD have shown that Aβ
dysregulation, detected by CSF levels or by PET, is the earliest detectable change, consistent
with Aβ as a trigger (Holtzman et al., 2011).
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The mechanism whereby Aβ leads to AD is less clear. Attention has focused on soluble
oligomers of Aβ (Aβo) as causing synaptic malfunction and loss of dendritic spines (Shankar
et al., 2008). In the only reported genome-wide unbiased screen for Aβo binding sites, we
identified PrPC (Lauren et al., 2009). Aβ binding to PrPC is high affinity and oligomer
specific (Chen et al., 2010; Lauren et al., 2009). In vivo, PrPC is not essential for certain Aβ-
related phenotypes, but is required for cell death in vitro, for reduced survival of APP/PS1
transgenic lines, for epileptiform discharges, for synapse loss, for serotonin axon
degeneration and for spatial learning and memory deficits (reviewed in (Um and
Strittmatter, 2013)). Critically, the ability of human AD brain-derived Aβ species to
suppress synaptic plasticity requires PrPC, and human AD brain contains PrPC-interacting
Aβo and Aβ–PrPC complexes (Barry et al., 2011; Freir et al., 2011; Um et al., 2012; Zou et
al., 2011).
Aβo–PrPC complexes signal to intracellular Fyn kinase (Larson et al., 2012; Um et al.,
2012). PrPC phenotypes in fish and worm require Fyn (Bizat et al., 2010; Malaga-Trillo et
al., 2009), Fyn regulates Glu receptor traffic and plasticity (Grant et al., 1992; Prybylowski
et al., 2005), and Fyn interacts with tau (Ittner et al., 2010; Roberson et al., 2011). Both PrPC
and Fyn are enriched in the Post-Synaptic Density (PSD), and Aβo engagement of PrPC
activates Fyn to phosphorylate NMDA receptors (Larson et al., 2012; Um et al., 2012).
The connection from Aβo–PrPC complexes to Fyn cannot be direct, because PrPC is
anchored via glycolipid to the plasma membrane while Fyn is cytoplasmic. Since both are
enriched in PSDs (Collins et al., 2006; Um et al., 2012), we hypothesized that a
transmembrane PSD protein might couple PrPC with Fyn. The PSD proteome includes 81
transmembrane proteins (Collins et al., 2006; Emes et al., 2008). Here, we screened PSD
transmembrane proteins for their ability to couple Aβo–PrPC with Fyn. We identified
mGluR5 as linking PrPC to Fyn. Activation of neuronal Fyn requires both mGluR5 and
PrPC. Aβo–PrPC can drive mGluR5-dependent calcium mobilization and eEF2
phosphorylation. Antagonists of mGluR5 prevent Aβo-induced dendritic spine loss and AD
transgene learning and memory deficits. These studies define an Aβo–PrPC–mGluR5
complex that leads to impaired neuronal function.
RESULTS
Screen for PSD Proteins Mediating Aβo/PrPC Signaling Identifies mGluR5
We considered the 81 known transmembrane PSD proteins as potential mediators (Fig. 1A,
B). We utilized a cell type in which PrPC and Fyn fail to couple. When PrPC and Fyn are
overexpressed in HEK293T cells, Aβo does not activate Fyn, as in neurons (Um et al.,
2012). We co-expressed PSD proteins together with PrPC and exposed the HEK cells to Aβo
prior to assessing Fyn activation by anti-phospho-SFK (Src Family Kinase) immunoblot
(Fig. 1B–D). In addition to 56 documented PSD proteins, we included APLP1 and APLP2,
due similarity with the PSD protein, APP, and known interaction with PrPC or Aβo (Bai et
al., 2008; Lauren et al., 2009; Schmitt-Ulms et al., 2004). We included the LRRTM family
because they organize synapses and modify Aβ levels (Linhoff et al., 2009; Majercak et al.,
2006). Of 61 proteins screened, only mGluR1 and mGluR5 increased Fyn activation by
more than two standard deviations (Fig. 1C, D). mGluR5 is reported to co-
immunoprecipitate and activate Fyn (Heidinger et al., 2002), to redistribute after Aβo
(Renner et al., 2010), to co-localize with Aβo (Renner et al., 2010), and to be required for
Aβo suppression of LTP (Rammes et al., 2011; Shankar et al., 2008; Wang et al., 2004).
In the initial screen with Aβo, mGluR1 or mGluR5 activity might have been ligand-
dependent or independent. While co-expression of either receptor results in baseline
activation of Fyn, only mGluR5 mediates Aβo activation (Fig. 1E–G). Neuronal Aβo-
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induced Fyn activation is PrPC–dependent, as for neurons (Um et al., 2012), because when
mGluR5 is expressed without PrPC, no Aβo regulation of Fyn occurs. In contrast, basal Fyn
activity (without Aβo) is independent of PrPC and equal for mGluR1 and mGluR5. Thus,
mGluR5 alone has the property of mediating Aβo–PrPC activation of Fyn in HEK cells.
Although EphB2 is not a PSD consensus member, we considered EphB2 as a link between
Aβo and Fyn because it couples with Fyn during development, and because Aβ alters EphB2
level (Cisse et al., 2011; Takasu et al., 2002). In HEK, co-expression of EphB2 and Fyn
yields kinase activation (Takasu et al., 2002), but EphB2 does not mediate Aβo signaling
(Suppl. Fig. S1).
We sought to determine if neuronal mGluR5 is required for Aβo-induced Fyn activation.
The mGluR5 negative allosteric modulator, MPEP, blocks Aβo-induced Fyn activation in
HEK cells (Fig. 1E) so we preincubated cortical neurons with MPEP, or the related MTEP,
prior to Aβo (Fig. 1H, J). Neither MTEP nor MPEP alters baseline Fyn activity, but both
eliminate Aβo-induced activation. The mGluR1 antagonist, MPMQ, does not prevent Aβo-
induced Fyn activation (Fig. 1H, J). We also cultured Grm5−/− cortical neurons and exposed
them to Aβo at 21DIV (Fig. 1I, J). Under basal conditions, phospho-Fyn levels were similar
to WT, but the increase by Aβo was eliminated. Thus, mGluR5, as well as PrPC, is required
for this Aβo signal transduction.
mGluR5 does not bind Aβo, but Physically Associates with PrPC and Fyn
With evidence that PrPC, mGluR5 and Fyn participate in Aβo signaling, we assessed
physical interaction amongst them. We visualized Aβo binding to COS-7 cells expressing
mGluR5, PrPC, both or neither (Fig. 2A, B). Aβo binding to PrPC-expressing cells is not
altered by mGluR5, and there is no detectable binding of Aβo to mGluR5 without PrPC.
PrPC alone accounts for Aβo surface binding.
If mGluR5 serves as a bridge between PrPC and Fyn, then it is predicted to interact
physically with both. We confirmed an association of mGluR5 with Fyn (Heidinger et al.,
2002), and observed no alteration by PrPC or Aβo (Suppl. Fig. 2A). Both mGluR1 and
mGluR5 associate with Fyn, but mGluR8 does not (Suppl. Fig. 2B). In HEK293T cells,
PrPC immunoprecipitates contain mGluR5, regardless of Aβo (Fig. 2C). Both mGluR1 and
mGluR5, but not mGluR8, co-immunoprecipitate with PrPC (Fig. 2D). We utilized this
specificity to examine whether discrete mGluR5 domains are responsible for PrPC
interaction (Suppl. Fig. 2C). Chimeric proteins containing the N-terminal globular domain
from one mGluR fused to the transmembrane domains from another mGluR were co-
expressed with PrPC. Each chimera co-immunoprecipitates PrPC less effectively than
mGluR5 (Suppl. Fig. 2D), suggesting that the PrPC–interacting regions are distributed in the
protein.
In brain, mGluR5 and PrPC are co-enriched in detergent-resistant PSD fractions (Fig. 2E)
(Collins et al., 2006; Um et al., 2012). To assess association of endogenous proteins
extractable with non-denaturing detergent, we covalently cross-linked proteins and then
precipitated PrPC. The PrPC immunoprecipitates contain mGluR5, but not mGluR8, NR2B
or GluR1 (Fig. 2F). Immunoprecipitates from Prnp−/− samples do not exhibit mGluR5.
Thus, Aβo–PrPC, PrPC–mGluR5, mGluR5–Fyn pairwise physical associations are
detectable.
To evaluate PrPC specificity for mGluR5, we applied soluble PrPC as a ligand to mGluR5-
expressing cells. PrP-His binds more avidly to COS-7 cells expressing mGluR5 than to non-
transfected or mGluR1-expressing or mGluR8-expressing cells (Suppl. Fig. S2E, F). Thus,
in this more stringent test of protein interaction, mGluR5, but not mGluR1 or mGluR8, has
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affinity for PrPC. We utilized similar conditions to examine soluble PrPC binding to neurons
with a human-specific anti-PrPC to selectively visualize immunoreactivity of the
recombinant ligand (Fig. 2G, H). Punctate binding of soluble PrPC along dendrites is visible
(Fig. 2G). This staining is reduced by 70% in Grm5−/− cultures, with the remaining signal
similar to the non-specific low-affinity level observed in non-transfected COS-7 cells (Supp.
Fig. S2E, F). We conclude that mGluR5 contributes significantly as a PrPC partner on the
neuronal surface.
Expression of PrPC plus mGluR5 Supports Aβo-Induced Increase of Intracellular Calcium
Activation of Fyn is one consequence of mGluR5 engagement, but activation of the
heterotrimeric GTPases, Gq/G11, with subsequent production of inositol (3,4,5)
trisphosphate (IP3) and release of intracellular calcium, is the more prominent pathway
(Luscher and Huber, 2010). We considered whether Aβo–PrPC might activate this pathway
by injecting RNA for mGluR5 and PrPC into X. laevis oocytes and applying a two-electrode
voltage clamp during bath perfusion of Aβo. G protein activation of phospholipase C leads
to IP3, calcium release and opening of an easily detected transmembrane chloride channel in
oocytes (Saugstad et al., 1996; Strittmatter et al., 1993). Glu-induced responses of 3000 nA
peak current at -60 mV are detected in oocytes expressing mGluR1 or mGluR5 (Fig. 3A, B).
PrPC does not alter the Glu responses. Bath application of Aβo had no effect on
conductances for uninjected oocytes, or oocytes expressing mGluR5 alone or PrPC alone
(Fig. 3C). However, in the double-expressing mGluR5-PrPC oocytes, Aβo produced an
inward current of 300–450 nA, 10% of the Glu-induced current. We included only mGluR
oocyte batches with Glu responses greater than 500 nA. For preparations with less than 500
nA responses to Glu, Aβo responses of 10% Glu magnitude may be present, but are not
prominent. The kinetics and reversal potential for the Aβo-induced signal were
indistinguishable from that of Glu acting on mGluR5 alone (Fig. 3A and not shown).
The specificity of the Aβo-induced current of PrPC–mGluR5 oocytes was examined. While
mGluR1 expression leads to equally strong Glu-induced current (Fig. 3A, B), there is no
detectable Aβo-induced current (Fig. 3A, C). PrPC lacking the Aβo binding domain,
PrPΔ23-111 (Chen et al., 2010; Lauren et al., 2009; Um et al., 2012), fails to support Aβo-
induced signaling through mGluR5 (Fig. 3C). The anti-PrPC antibody, 6D11, binds to
residues 95–105 and prevents Aβo interaction (Chung et al., 2010; Lauren et al., 2009; Um
et al., 2012). Preincubation with 6D11 blocks Aβo responses, but not Glu responses, in
PrPC-mGluR5 oocytes (Fig. 3B, C). The Aβo–induced response has an EC50 of 1 μM
monomer equivalent, an estimated 10 nM oligomer concentration (Fig. 3D). A characteristic
of G protein mediated responses in Xenopus oocytes is strong desensitization. Maximal Glu
stimulation nearly eliminates subsequent responses to Glu for 10–15 min. Consistent with
the Aβo–PrPC–mGluR5 responses sharing this pathway, pretreatment with Glu eliminates
the response to subsequent Aβo (Fig. 3E). In addition, pretreatment with cell permeable
BAPTA-AM to chelate intracellular calcium abrogated the Aβo-induced signal (Fig. 3E), as
for Glu (Saugstad et al., 1996). Thus, Aβo interaction with a PrPC–mGluR5 complex
mobilizes calcium stores. While mGluR5-mediated signaling to Fyn is as robust with Aβo–
PrPC as with Glu, signaling to calcium mobilization is substantially less effective for Aβo–
PrPC than with Glu as the mGluR5 ligand, so Aβo does not mimic Glu precisely.
Acute Aβo-Induced Calcium Signals in Neuronal Culture Require mGluR5 and PrPC
We considered whether Aβo regulates neuronal calcium signaling through mGluR5 directly
and acutely. Chronic Aβo–PrPC–Fyn signaling can indirectly alter NMDA-R trafficking to
modulate NMDA-induced calcium responses (Um et al., 2012). We used a calcium-sensitive
fluorescent dye to assess direct immediate response to Aβo in 21DIV cortical cultures. In
low-density cultures, there is little direct calcium response to Aβo under the conditions that
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modulate NMDA-R responses (not shown and (Um et al., 2012)). With microscopic
imaging, Aβo occasionally induces local calcium transients, but there is no generalization
and measurement across a microtiter well does not detect a change (not shown). Higher
density cultures exhibit spontaneous synchronized calcium increases (Suppl. Fig. S3A) that
depend on network connectivity being suppressed by TTX, CNQX, or APV (Suppl. Fig.
S3B, C) (Dravid and Murray, 2004). Under these conditions, Aβo induces an increase of
intracellular calcium (Fig. 4A). Averaging multiple wells smoothes random spontaneous
signals (Suppl. Fig. S3A), and Aβo-induced responses are apparent (Fig. 4A). This response
is oligomer specific; no response is detected with monomeric Aβ (Fig. 4C). In either Grm5−/
− or Prnp−/− neurons, the spontaneous synchronized calcium signals are indistinguishable
from WT (Suppl. Fig. S3D, E). However, Aβo fails to induce a calcium signal in networks
lacking either PrPC or mGluR5 (Fig. 4B).
To assess whether similar responses occur with human autopsy tissue, we utilized TBS-
soluble extracts from human brain, which we have previously characterized for PrPC–
interacting Aβ species and for Fyn activation in mouse cultures (Suppl. Table S1 and (Um et
al., 2012)). In high-density cortical cultures, dialyzed TBS-soluble brain extracts from AD
cases generate greater calcium mobilization than do Control brain extracts (Fig. 4D, E;
P<0.001). Moreover, the level of PrP(23-111)-interacting Aβ in human brain samples
correlates with the magnitude of the calcium response (Fig. 4F). Pre-absorption with anti-Aβ
antibody removes PrPC-interacting Aβ immunoreactivity (Suppl. Fig. S3H) and reduces the
calcium response (Suppl. Fig. S3F, G). Preabsorption with PrP-Fc, but not control Fc resin,
removes PrPC-interacting species and reduces the calcium response (Fig. 4G, Suppl. Fig.
S3I). Thus, PrPC–interacting Aβ species in human AD brain TBS-soluble extracts stimulate
calcium signals in high-density neuronal cultures. These responses require network
connectivity, and are blocked by TTX, CNQX or APV (Suppl. Fig. S4J). The mGluR5
antagonists, MPEP and MTEP, block the AD brain extract response (Fig. 4I). In contrast, the
mGluR1 antagonist MPMQ does not block the AD extract-induced response (Fig. 4I).
Furthermore, the ability of human AD brain extract to induce a calcium signal is eliminated
in Grm5−/− or Prnp−/− neurons (Fig. 4H).
We considered the source of calcium for the AD extract-induced signal and its relationship
to Fyn. Thapsigargin (TG) pretreatment prevented signaling, consistent with release from
endoplasmic reticulum stores (Fig. 4I). In contrast, TG pretreatment did not prevent Fyn
activation (Fig. 4J, K) and inhibition of Fyn with saracatinib did not prevent calcium
signaling (Fig. 4I). While Fyn and calcium signaling by AD extracts require both PrPC and
mGluR5, the two mediators appear pharmacologically separable.
Chronic Aβo has the potential to desensitize mGluR5 calcium responses. We assessed this in
two models: HEK293 cells expressing mGluR5 and PrPC, and low density cultured neurons.
HEK–mGluR5 cells respond to Glu with calcium elevation and there is no effect of Aβo pre-
incubation (Supp. Fig. S4A, B, F). For HEK cells stably expressing mGluR5 and PrPC,
baseline Glu responses are similar, but Aβo preincubation suppresses Glu responses by 50%
in independent clones (Suppl. Fig. S4A, C, D, F). This effect requires the Aβo-binding
PrP(23-111) domain because clones expressing a truncation mutant fail to bind Aβo (Suppl.
Fig. S5A), and show no Aβo suppression of Glu-induced calcium (Suppl. Fig. S4E, F). Aβo-
induced suppression of mGluR5 responses is also observed in neurons. In low density
cultures, there are no spontaneous synchronized calcium oscillations, but the mGluR5
agonist, DHPG, results in synchronized oscillations (Suppl. Fig. S4G). Pretreatment with
Aβo nearly eliminates DHPG-induced oscillations in WT neurons (90% inhibition, Suppl.
Fig. S4H, I). The Aβo suppression of DHPG-induced oscillations is limited to 40% in Prnp
−/− cultures (Suppl. Fig. S4I).
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Multiple mechanisms contribute to mGluR5 desensitization, including protein kinase C,
calcium/calmodulin binding and receptor internalization. We assessed the effect of Aβo and
the group I mGlu receptor agonist, DHPG, on cell surface mGluR5 levels using biotinylation
of live neurons with a cell impermeable reagent (Suppl. Fig. S4J–L). At 1 hour, DHPG
reduces surface mGluR5 by 20%, as described (Choi et al., 2011). In contrast, Aβo treatment
generates a PrPC-dependent 25% increase in surface/total mGluR5 ratios (Suppl. Fig. S4J–
L). The increase after Aβo addition may reflect “trapping” of mGluR5 in relatively
immobile complexes (Renner et al., 2010). Despite this difference between Aβo and DHPG
in mGluR5 trafficking, Aβo treatment suppresses mGluR5 signaling (Suppl. Fig. S4H, I).
Aβo Signals through PrPC and mGluR5 to Protein Translation Machinery
Metabotropic GluRs have effects on protein translation (Luscher and Huber, 2010), as well
as calcium release and Fyn. We examined whether Aβo–PrPC–mGluR5 coupling might alter
phosphorylation of eukaryotic elongation factor 2 (eEF2). The mGluR5 agonist, DHPG,
drives eEF2-56T phosphorylation (Suppl. Fig. S5A). Aβo treatment has a similar effect on
eEF2 phosphorylation (Fig. 5A, B, Suppl. Fig. S5A–C). Mediation of the Aβo effect by
mGluR5 is demonstrated by inhibition with MTEP (Suppl. Fig. S5B, C). In contrast, the
mGluR1 antagonist, MPMQ, does not prevent Aβo-induced eEF2 phosphorylation (Suppl.
Fig. S5D, E). Genetic analysis with Prnp−/− and Grm5−/− neurons confirms that the Aβo
effect on eEF2 phosphorylation depends on these proteins (Fig. 5A, B). Aβo-induced eEF2
phosphorylation is detected in dendrites, and is absent in Prnp −/− and Grm5 −/− neurons
(Fig. 5C, D). The addition of both Aβo and DHPG produced no greater eEF2
phosphorylation than either ligand alone, consistent with occlusive action (Suppl. Fig. S5F,
G).
Dendritic translation of Arc is under mGluR5 control, via an eEF2-dependent mechanism
(Park et al., 2008). As predicted from the mGluR5-mediated action of Aβo on p-eEF2,
dendritic Arc immunoreactivity is elevated after 5 min Aβo exposure (Fig. 5E, F) and Arc
immunoblot signal increases in brain slices (Suppl. Fig. S5H, I).
To extend the AD relevance of these observations, we tested whether human AD extracts
generated a similar pattern. Pooled TBS-soluble extracts from AD brain, but not Control
brain, elevated eEF2 phosphorylation in WT mouse 21DIV neurons (Fig. 5G, H). This
signaling is not observed in Grm5−/− and Prnp−/− cultures. Thus, Aβo–PrPC complexes
signal through mGluR5 to modify Fyn activation, calcium levels and eEF2 phosphorylation.
We considered how Aβo-induced eEF2 phosphorylation relates to Fyn activation and
calcium signaling. Saracatinib suppresses basal p-SFK levels and prevents Aβo stimulation
of Fyn (Fig. 5I), and also prevents Aβo-induced eEF2 phosphorylation (Fig. 5I, K).
Thapsigargin pretreatment prevents AD extract-induced calcium signaling (Fig. 4H), and
also prevents eEF2 phosphorylation (Fig. 5J, K). Thus, eEF2 regulation by Aβo requires
both Fyn and calcium signaling.
Cellular Effects of Aβo Require mGluR5
Time-lapse imaging of myristoyl-GFP expressing neurons (Fig. 6A) has shown that Aβo
leads to a loss of 10% of dendritic spines over 5 hours by a Prnp– and Fyn–dependent
mechanism (Um et al., 2012). Acute DHPG treatment leads to immature spines, reduced
spine volume and fewer surface AMPA receptors during chemical LTD (Abu-Elneel et al.,
2008; Moult et al., 2006; Vanderklish and Edelman, 2002), while chronic DHPG results in
decreased spine density (Shinoda et al., 2010). We tested whether mGluR5 blockade
prevents Aβo-induced spine loss. MPEP treatment does not alter baseline spine stability over
5 h, but prevents Aβo–induced loss (Fig. 6A, B). Deletion of mGluR5 also prevents Aβo-
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induced spine loss (Fig. 6A, C). Thus, mGluR5 participates in morphological effects of
Aβo–PrPC complexes.
The Aβo–PrPC–Fyn pathway contributes to short-term LDH release from neurons (Um et
al., 2012). Either addition of the mGluR5 negative allosteric modulator, MTEP, or deletion
of the Grm5 gene prevents Aβo-induced LDH release (Fig. 6D, E).
mGluR5 Antagonist Reverses Behavioral Deficits in FAD Transgenic Mice
The double transgenic APPswe/PS1ΔE9 (APP/PS1) mouse exhibits normal behavior
through age 6 months, and then progressively loses learning and memory (Gimbel et al.,
2010; Jankowsky et al., 2003). We considered a role for mGluR5. As reported (Lu et al.,
1997; Xu et al., 2009), constitutive mGluR5 deletion impairs performance (Suppl. Fig. S6).
Treatment of WT mice with high dose MTEP, 40 mg/kg, impairs alertness and EEG
amplitude (Suppl. Fig. S6). Thus, we sought to achieve partial inhibition of mGluR5 with 15
mg/kg MTEP, which does not alter EEG rhythm (Suppl. Fig. S6).
First, we treated WT and APP/PS1 mice with vehicle or MTEP and assessed spatial learning
in the radial arm water maze (Fig. 7A). Mice at 9 months age were randomized to blinded
treatment with vehicle or MTEP (15 mg/kg, B.I.D. for 10 days) for 3 days prior to, and then
for 7 days throughout memory testing. Learning is impaired in transgenics relative to WT,
but is fully recovered with MTEP. There is a significant interaction of genotype and drug
(two-way repeated-measures (RM) ANOVA: APP/PS1xMTEP interaction, P<0.01; APP/
PS1, P<0.01; MTEP, P<0.01).
We extended this finding with alternative memory tests and additional cohorts. Without
MTEP treatment, APP/PS1 mice at 9 months age are unable to distinguish novel and
familiar objects, whereas WT mice exhibit novel object preference (Fig. 7B; P<0.001 for
WT). Exploration of two novel objects is not different between genotypes during
acclimation (not shown). MTEP-treated APP/PS1 mice recover a novel object preference
(Fig. 7B; P<0.001 for both WT and APP/PS1 with MTEP).
A separate cohort of APP/PS1 was tested in the Morris water maze. Without treatment, the
APP/PS1 mice show greater latencies to locate a hidden platform relative to WT across
learning trials (Fig. 7C, RM-ANOVA, P<0.001), and spend less time in the target quadrant
during a probe trial for memory 24-hours later (Fig. 7D, ANOVA P<0.001). In contrast,
MTEP-treated APP/PS1 mice are indistinguishable from untreated WT or MTEP-treated
WT mice in learning and memory (Fig. 7C, D), but are different from untreated APP/PS1
(Fig. 7C, D; P<0.001). There is a significant interaction of genotype and drug (two-way
RM-ANOVA in C for APP/PS1xMTEP interaction, P<0.001; two-way ANOVA in D,
P<0.001).
We also administered MTEP to 3XTg mice expressing mutant APP, PS1 and Tau (Oddo et
al., 2003). At 8–9 months, these mice perform normally in the Morris water maze (not
shown), but are impaired in novel object recognition (Fig. 7E). After randomization to
MTEP or vehicle, the 3XTg mice were assessed for novel object recognition (Fig. 7G).
MTEP-treated 3XTg mice show a novel object preference (P<0.01), but vehicle-treated mice
do not. Thus, MTEP reverses memory deficits in two transgenic AD mice.
We considered whether improved memory with MTEP is correlated with a reversal of
synaptic loss. A separate cohort of WT and APP/PS1 transgenic mice at 10 months age were
treated for 10 days with MTEP, 15 mg/kg B.I.D. As expected, control APP/PS1 mice exhibit
a 25–30% decrease in area occupied by presynaptic synaptophysin and postsynaptic PSD-95
immunoreactivity in the dentate gyrus (Fig. 8A–C). The loss of stained synaptic area was
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fully rescued by a 10-day course of MTEP (Fig. 8D, E). For WT mice, MTEP did not alter
synaptic density. We also assessed synaptic density ultrastructurally, identifying synaptic
profiles by the presence of a post-synaptic density and presynaptic vesicles (Fig. 8F).
Synapse density in transgenic dentate gyrus increased by 20% with MTEP treatment (Fig.
8G).
DISCUSSION
This study delineates a direct role for mGluR5 in Aβo-related pathophysiology. Of
transmembrane PSD proteins, only mGluR5 supports coupling of Aβo–PrPC to Fyn
activation. Intracellular calcium and protein translation are also linked to Aβo–PrPC
engagement via mGluR5. An mGluR5 dependence of signaling is observed for TBS-soluble
extracts of AD brain as well as synthetic Aβo, emphasizing the disease relevance. A co-
receptor role for mGluR5 is required for dendritic spine loss and transgenic memory
impairment. Together, these findings delineate mGluR5 activation as a critical step in Aβo
signal transduction with potential for therapeutic intervention.
Dysregulation of mGluR5 signaling in AD
Several previous studies have indirectly implicated mGluR5 in Aβo signaling and in AD.
Aβo alters mGluR5 trafficking in neurons, with reduced diffusion, clustering, aberrant
activation and neurotoxicity (Renner et al., 2010). The results here provide a PrPC-based
mechanism for these findings and for downstream signaling. Aβo from synthetic, cellular
and human AD brain sources suppresses LTP and enhances LTD. These actions are
mimicked by mGluR5 agonists and inhibited by mGluR5 antagonists (Rammes et al., 2011;
Shankar et al., 2008; Wang et al., 2004). In human AD, mGluR ligand binding is decreased
in brain relative to controls and the loss is correlated with disease progression (Albasanz et
al., 2005). Proteins titrated by mGluRs, eEF-2, Arc and p70 S6 kinase, are dysregulated in
AD brain (An et al., 2003; Li et al., 2005; Wu et al., 2011).
Signaling downstream of mGluR5
Canonical mGluR5 signaling couples to Gq/G11 GTPases that activate phospholipase C to
produce IP3 and release calcium stores (Luscher and Huber, 2010). mGluR5 also modulates
plasma membrane potassium, calcium and TRP channels. Src family tyrosine kinases,
including Fyn, have been implicated in linking to NMDA-R (Heidinger et al., 2002;
Nicodemo et al., 2010). The proline rich tyrosine kinase 2 (Pyk2) participates in Src/Fyn
interaction with mGluR signaling (Heidinger et al., 2002; Nicodemo et al., 2010). The
calcium/calmodulin–dependent eEF2 kinase (eEF2K) is bound to mGluR5 in the basal state,
but is released during activation to phosphorylate eEF2 (Luscher and Huber, 2010).
Phospho-eEF2 reduces global translation, but allows increased Arc/Arg3.1 expression (Park
et al., 2008). The Homer family plays a role in mGluR signaling, interacting with receptor
and eEF2K (Hu et al., 2010; Luscher and Huber, 2010; Ronesi et al., 2012). Homer
interactions with SHANK contribute to PSD localization, specific isoforms have roles in
homeostatic scaling.
We show that Aβo–PrPC complexes leads to several mGluR5 outputs. Fyn activation by Aβo
in cortical neurons requires mGluR5 genetically and pharmacologically. Fyn is implicated in
Aβo-induced dysregulation of NMDA-R trafficking and activation (Um et al., 2012).
Because Fyn binds directly to Tau (Ittner et al., 2010; Lee et al., 2004), this may have
implications for AD beyond dysregulation of GluRs.
The Aβo–PrPC–mGluR5 complex also activates phospholipase C, as detected by monitoring
calcium-activated chloride channels in oocytes. The ability of Aβo or human AD brain TBS-
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soluble extract to increase calcium in cortical neurons requires mGluR5 and PrPC. The
calcium increase in neurons may occur by the IP3 pathway and also by regulation of
NMDA-Rs. Fyn activation by Aβo–PrPC is as strong as that by Glu, whereas calcium
mobilization appears to be an order of magnitude less effective for Aβo PrPC–than for Glu.
Divergence in Aβo–PrPC–mGluR5 signaling requires further study.
Protein translation plays a major role in mGluR5 signaling (Luscher and Huber, 2010). The
phosphorylation of eEF2 is increased by Aβo–PrPC as much as by mGluR5 agonist.
Therefore dysregulation of translation may contribute to synaptic dysfunction in AD. Arc is
one protein target of mGluR5 signaling that is up-regulated by Aβo acutely. Calcium and
Fyn are independent mediators, which appear to cooperate in eEF2 phosphorylation.
We show that mGluR5 antagonists prevent Aβo-induced spine loss from hippocampal
neurons in vitro and in vivo. Critically, MTEP reverses memory deficits in transgenic AD
models. Multiple signaling pathways from Aβo–PrPC–mGluR5 complexes are likely to
participate. For spine loss in vitro, Fyn is required (Um et al., 2012), but other mGluR5
signaling components may contribute. Protein translation, calcium release and Fyn kinase
are each known to participate in plasticity, learning and memory.
Feedback of mGluR5 signaling on Aβ levels
The mGluR5 pathway may also feedback on APP/Aβ metabolism to exacerbate AD.
Specifically, mGluR5 agonism elevates Arc, which enhances Aβ production by participating
in APP and PS1 co-localization within endocytic vesicles (Wu et al., 2011). Shared
pathways between AD and Fragile X have been reported (Sokol et al., 2011). The FRMP
protein normally represses APP translation. Transgenic mice with both APP transgenes and
loss of FRMP have enhanced phenotypes, including audiogenic seizures, which are treatable
with MPEP.
mGluR specificity and localization
Of mGluR receptors, only mGluR1 and mGluR5 interact with Fyn and PrPC. Only mGluR5
mediates Aβo-induced stimulation of Fyn and calcium signaling in oocytes. Grm5 gene
deletion, and mGluR5-specific compounds reverse Aβo phenotypes, including Fyn
activation, neuronal calcium mobilization, eEF2 phosphorylation, spine loss, LDH release
and memory deficits. The mGluR1-specific antagonist, MPMQ, does not block. Thus,
mGluR5 appears to be specifically involved in Aβo–PrPC action.
PrPC, mGluR5 and Fyn have all been localized to the PSD by subcellular fractionation. For
PrPC and Fyn, high-resolution in situ protein localization in brain has not been reported. For
mGluR5, imaging confirms a post-synaptic localization and indicates that mGluR5 is
dynamically located at the PSD periphery (Lujan et al., 1996). Dynamic regulation of
mGluR5 localization by Aβo has been observed (Renner et al., 2010).
Short term activation versus longer term desensitization
While ionotropic receptors function rapidly, metabotropic receptors are slow and show
prominent desensitization. Aβo levels are highly unlikely to fluctuate on the time scale of
synaptic transmission, so Aβo–PrPC complexes may engage mGluR5 and elicit a degree of
desensitization that prevents responsiveness to cyclic changes in Glu. Thus, mGluR5 may be
dysregulated by acute activation and chronic desensitization.
Alternate ligands and accessory ectodomains for mGluRs
Activation of mGluR5 by Aβo–PrPC complexes expands the repertoire of metabotropic
glutamate receptors. Certain other G protein coupled receptors (GPCRs) respond to more
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than one ligand, and interact extracellularly with accessory subunits or co-receptors.
Melanocortin receptors recognize both melanocortin agonists and Agouti/AgRP antagonists
with specificity modified by MRAPs (Breit et al., 2011). Calcitonin and related receptors
have ligand preference altered by transmembrane RAMPs (Hay et al., 2006). Non-canonical
signaling by Hedgehogs and Wnts through Smoothened and Frizzleds to heterotrimeric G
proteins depends on ligand interaction with Patched and LRP5/6, respectively (Angers and
Moon, 2009; Robbins et al., 2012). Ectodomain accessory proteins for mGluRs have not
been recognized previously, so PrPC is unique. The only previously known endogenous
ligand for mGluR5 is Glu, so the action of Aβo–PrPC is novel. Our findings raise the
possibility that mGluR5 may be regulated physiologically by molecules other than Glu.
Targeting mGluR5 for AD therapy
The delineation of an Aβo–PrPC–mGluR5–Fyn pathway provides potential targets for AD
intervention. Antibodies that block Aβo binding to PrPC reverse memory deficits in
transgenic AD mice (Chung et al., 2010) and we show that a mGluR5 negative allosteric
modulator has a similar effect. However, full mGluR5 antagonism may have deleterious
effects on neuronal function and impairment of baseline attention (Luscher and Huber, 2010;
Simonyi et al., 2010). Deficits of contextual fear conditioning and inhibitory learning are
observed in the absence of mGluR5 (Xu et al., 2009), and mGluR5 function may contribute
to healthy brain aging (Lee et al., 2005; Menard and Quirion, 2012; Nicolle et al., 1999).
Optimal intervention may therefore be designed to prevent Aβo–PrPC activation of mGluR5,
without modifying Glu activation of mGluR5.
EXPERIMENTAL PROCEDURES
Mouse strains
The mouse strains have been described previously (Gimbel et al., 2010; Jankowsky et al.,
2003; Lu et al., 1997; Oddo et al., 2003).
Cell Culture and Biochemistry
Standard procedures were utilized, including the assessment of intracellular calcium level in
neuronal culture (Um et al., 2012) and voltage clamp recording from X. laevis oocytes
(Lauren et al., 2009; Strittmatter et al., 1993). Fresh-frozen post-mortem human pre-frontal
cortex from the brains of AD patients were obtained, as approved by Institutional Review
Board collected at NYU and at Yale. Particulate components were removed from TBS
homogenates by centrifugation at 100,000 x g for 30 minutes.
MTEP treatment and memory testing of transgenic mice
Mice were randomized to treatment groups and the experimenter was unaware of treatment
status throughout behavioral testing. Procedures for Morris water maze testing have been
described (Gimbel et al., 2010).
Extended Experimental Procedures are available in the online supplement.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Metabotropic GluR5 Links Aβo/PrPC Complexes to Fyn
A Schematic indicating that Aβo/PrPC complexes require a co-receptor to activate Fyn in
PSDs.
B Pie charts show transmembrane proteins (81) among total PSD proteins (651).
Transmembrane proteins were subdivided; those that were screened in Aβo/Fyn assays (56,
yellow) and those not (25, gray).
C Immunoblot of screening for Fyn activation. HEK293T cells were transfected with
expression vectors for Fyn, PrPC or candidate genes. After treatment with 1 μM Aβo for 15
min, lysates were analyzed by anti-phospho-SFK (Tyr 416) or anti-Fyn immunoblot.
D The ratio of phospho-SFK to Fyn is plotted from 3 experiments with Aβo. Blue line
indicates the mean of all controls. Dark gray is one standard deviation, and light gray is two
standard deviations from control.
E HEK293T cells were transfected with vectors for Fyn, PrPC or mGluR5, and treated with
0 or 1 μM Aβo for 15 min. Some cultures were pre-incubated for 30 min with 100 μM
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MPEP prior to Aβ. Lysates were analyzed by anti-phospho-SFK (Tyr 416), anti-Fyn, anti-
mGluR5, or anti-PrPC immunoblot. Actin is loading control.
F HEK293T cells were transfected with vectors for Fyn, PrPC or Myc-mGluR1 as indicated.
After cell treatment with 0 or 1 μM Aβo for 15 min, lysates were analyzed by anti-phospho-
SFK (Tyr 416), anti-Fyn, anti-Myc, or anti-PrPC immunoblot. Actin is loading control.
G Quantification of phospho-SFK level in lysates from E, F, normalized to Fyn. Mean±sem,
n=4 experiments. **, P<0.01; *, P<0.05; ANOVA, Tukey post-hoc pairwise comparisons.
H Cortical neurons from E17 WT mice at 21 DIV were treated with 0 or 1 μM of Aβo for 15
min. Indicated samples were treated with 100 μM MTEP or 10 μM MPMQ for 30 min prior
to Aβo. Lysates were subjected to immunoblot with anti-Fyn, or anti-phospho-SFK (Tyr
416). Actin is loading control.
I Cortical neurons from WT or Grm5−/− mice after 21 DIV were treated with 0 or 1 μM
Aβo for 15 min. Lysates were analyzed by anti-phospho-SFK (Tyr 416), anti-Fyn, anti-
mGluR5 immunoblot. Actin is loading control.
J Quantification of phospho-SFK level in lysates from H, I, normalized to Fyn. Mean±sem,
n=3 experiments. ***, P<0.001; *, P<0.05; ANOVA, Tukey post-hoc pairwise comparisons.
See also Fig. S1.
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Figure 2. PrPC Interacts with mGluR5
A Aβo (250 nM) binding to COS7 cells expressing mGluR5, PrPC, or co-expressing
mGluR5 with PrPC (upper). Protein expression was confirmed by immunofluorescence
(bottom). Scale bar, 50 μm.
B Dose-response for Aβo binding to COS7 cells from experiments as in A. Mean±sem, n=3
experiments.
C HEK293T cells were transfected with vector for either mGluR5 or PrPC, or co-transfected
for mGluR5 and PrPC. After treatment with 0 or 1 μM Aβo for 1 h, lysates (input) and anti-
PrPC immunoprecipitates were immunoblotted with either anti-mGluR5 or anti-PrPC.
D HEK293T cells were transfected with vector for PrPC or co-transfected with different
Myc-tagged mGluRs and PrPC, as indicated. Lysates (input) and anti-Myc
immunoprecipitates were immunoblotted with either anti-Myc or anti-PrPC antibodies.
E Indicated fractions (20 μg protein) were prepared and analyzed by immunoblot with anti-
PrPC, anti-mGluR5, anti-EphB2, anti-PSD95, anti-synaptophysin, and anti-actin antibodies.
F Brain lysates from WT or Prnp −/− mice were cross-linked with the cleavable DTSSP.
Whole lysates (5% Input) and anti-PrPC immunoprecipitates were immunoblotted with anti-
mGluR5, anti-mGluR8, anti-NR2B, anti-GluR1 or anti-PrP antibodies. Asterisk, Ig light
chain.
G His-tagged human PrPC was incubated with DIV21 WT or Grm5 −/− neurons for 1 h.
Neurons were then fixed and stained with human-specific anti-PrPC antibody and Alexa-568
secondary antibody with rhodamine-phalloidin as counterstain. Scale bar, 10 μm.
H Quantification of His-PrPC bound to WT or Grm5 −/− neurons. His-PrPC
immunofluorescence was measured by ImageJ in segments of primary dendrites 10 μm from
the soma and background-subtracted. Mean±sem, n=3 embryos for each genotype.***,
P<0.001; Student’s two-tailed t test.
See also Fig. S2.
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Figure 3. Aβo directly stimulate mGluR5
A Representative traces obtained from oocytes expressing mGluR5 plus PrPC, or mGluR1
plus PrPC. Bath application (bars) of Aβo (1.5 μM monomer equivalent, estimated 15 nM
oligomer) or Glu (100 μM) elicits an inward current from mGluR5 plus PrPC oocyte.
Exposure to Glu, but not Aβo, elicits a response in oocytes expressing mGluR1 and PrPC.
B, C Quantification of the peak current elicited by glutamate (B) or Aβo (C) in oocytes
expressing the indicated proteins, with or without pre-treatment with 5 μg/ml anti-PrPC
antibody, 6D11. Data are Mean±sem, n=8–28 oocytes. **, P<0.01; ANOVA, Tukey post-
hoc pairwise comparisons.
D Dose response for Aβo-induced current in oocytes expressing mGluR5 and PrPC. Mean
±sem for n = 4–7 oocytes.
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E Oocytes expressing mGluR5 and PrPC were either treated for 1 min with 100 μM Glu to
maximally stimulate a response 3 min prior to testing for an Aβo response, or not pre-
stimulated with Glu. Alternatively, some oocytes were preincubated with 100 μM BAPTA-
AM for 60 minutes. After these pretreatments, the peak inward current was measured in
response to 1.5 μM Aβo. Mean±sem, n=6–12 oocytes. **, P<0.005; ANOVA, Tukey post-
hoc pairwise comparisons.
See also Fig. S4.
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Figure 4. Aβ species from human AD brains or synthetic Aβo increase intracellular calcium via
PrP and mGluR5
A Change of intracellular calcium in E17 cortical neurons from WT, Prnp −/− or Grm5 −/−
mice in response to Aβo, vehicle (Veh) or ionomycin (500 nM) was monitored by FLIPR
calcium assay. Mean±sem, n=24–40 wells from 3–5 embryos per genotype.
B Quantification of calcium response induced by Aβo or vehicle (Veh) from A. *, P<0.05,
**, P<0.01 ***, P<0.001; ANOVA, Tukey post-hoc pairwise comparisons.
C Quantification of calcium response induced by oligomeric Aβ (Aβo), monomeric Aβ
(Aβm) or vehicle (Veh). ***, P<0.001; ANOVA, Tukey post-hoc pairwise comparisons.
D Intracellular calcium in E17 cortical neurons in response to human AD brain extracts
(AD), n=25, age-matched control brain (Con), n=19 (1.5 μg total protein/ml) or ionomycin
(500 nM) monitored by FLIPR calcium assay. Mean±sem, ***, P<0.001 by Repeated
Measures ANOVA for 10 seconds window after AD brain extract.
E Quantification of calcium response induced by AD or Con extracts from C. Each dot is
from a different brain. ***, P<0.001 by Student’s two-tailed t test.
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F Correlation between AD extract-induced calcium and PrP(23-111)-interacting Aβ species
is plotted. Each point is from a different brain sample. Pearson coefficient of linear
correlation reported with two-tailed P.
G Calcium response induced by AD extracts preabsorbed with Fc (AD Fc) or PrPC-Fc resin
(AD PrP-Fc), or Con extracts preabsorbed with Fc (Con Fc) or PrPC-Fc resin (Con PrP-Fc).
*, P<0.05, **, P<0.01; ANOVA, Tukey post-hoc pairwise comparisons.
H Calcium response induced by AD or Con extracts in E17 cortical neurons from WT, Prnp
−/− or Grm5−/− mice. Mean±sem, n = 3 independent embryos for each genotype. *, P<0.05,
**, P<0.01; ANOVA, Tukey post-hoc comparisons.
I Calcium response induced by AD or Con extracts in WT cortical neurons. Neurons were
pretreated with 100 μM MPEP, 100 μM MTEP, 10 μM MPMQ, 500 nM saracatinib for 1 h
or 100 nM thapsigargin for 24 h prior to AD extract. *, P<0.05, **, P<0.01, ***, P<0.001;
ANOVA, Tukey post-hoc pairwise comparisons to AD extract only samples.
J WT cortical neurons were treated with 0 or 1 μM Aβo for 15 min. Indicated sample was
treated with 100 nM thapsigargin for 24 h prior to Aβo. Lysates were analyzed by anti-
phospho-SFK or anti-Fyn immunoblot.
K Quantification of phospho-SFK level in the lysate normalized to Fyn from 3 experiments.
Mean±sem, *, P<0.05; **, P<0.01; ANOVA, Tukey post-hoc pairwise comparisons.
See also Fig. S3.
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Figure 5. eEF2 phosphorylation is enhanced by Aβo through PrP and mGluR5
A DIV21 cortical neurons from WT, Prnp−/− or Grm5−/− mice were treated with 0 or 1 μM
Aβo for 5 min. Lysates were analyzed by anti-phospho-eEF2, or anti-eEF2 immunoblot.
GAPDH is loading control.
B Phospho-eEF2 level in the lysate normalized to eEF2. WT, n=3; Prnp−/−, n=3; Grm5−/−,
n=3. Mean±sem, **, P<0.01; Student’s two-tailed t test.
C Immunohistology of DIV21 WT, Prnp−/− or Grm5−/− cortical neurons stained with anti-
phospho-eEF2 and anti-MAP2 antibodies after exposure of 0 or 1 μM Aβo. Scale bar, 10
μm.
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D Phospoho-eEF2 intensity normalized to MAP2 signal. WT, n=3; Prnp−/−, n=3; Grm5−/−,
n=3. 8–10 images were analyzed per experiment. Mean±sem, ***, P<0.001; Student’s two-
tailed t test.
E Immunohistology of DIV 21 WT neurons stained with anti-Arc antibody after 1 μM Aβo
for 5 min. Scale bar, 5 μm.
F Arc intensity in dendrites after 1 μM Aβo or 100 μM DHPG for 5 min. For dendritic Arc
levels, average pixel intensity was measured in secondary dendrites 10 μm from first branch
point. WT, n=6. Mean±sem, **, P<0.01, *, P<0.05; ANOVA, Tukey post-hoc pairwise
comparisons.
G DIV21 cortical neurons from WT, Grm5−/− or Prnp−/− mice were treated with human
control or AD brain extracts (30 μg total protein/ml) for 5 min. Lysates were analyzed by
anti-phospho-eEF2 or anti-eEF2 immunoblot.
H Phospho-eEF2 level normalized to eEF2 from G. WT, n=6; Grm5−/−, n=4; Prnp−/−, n=3.
Mean±sem, *, P<0.05; **, P<0.01; ***, P<0.001; ANOVA, Tukey post-hoc pairwise
comparisons.
I, J WT cortical neurons were treated with 0 or 1 μM Aβo for 15 min. Indicated samples
were treated with 500 nM saracatinib for 1 hour (I) or 100 nM thapsigargin (TG) for 24
hours (J) prior to Aβo. Lysates were analyzed by anti-phospho-SFK, anti-Fyn, anti-phospho-
eEF2, or anti-eEF2 immunoblot. GAPDH is loading control.
K Phospho-eEF2 level normalized to eEF2 from 3 experiments. Mean±sem, *, P<0.05;
ANOVA, Tukey post-hoc pairwise comparisons.
See also Fig. S5.
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Figure 6. Aβo-induced toxicity is blocked by mGluR5 antagonists
A Hippocampal neurons (21DIV) expressing myristoyl-GFP from WT or Grm5−/− mice
were imaged for 6 h with or without MPEP (100 μM). Aβo (500 nM monomer equivalent)
or vehicle was added at 1 h. Note loss of several spines after Aβo addition in the WT
neurons. Scale bar, 1 μm.
B, C Dendritic spine loss over 5 hours is plotted as a function of Aβo and MPEP (B) or
Grm5 genotype (C). Mean±sem, n=3–5 cultures from separate mice of each genotype. *,
P<0.05; **, P<0.01; ANOVA, Tukey post-hoc pairwise comparisons.
D Neurons at DIV21 from WT mice were treated with 0 or 1 μM Aβo for 2 h. Some cultures
were treated with 100 μM MTEP for 1 h prior to Aβo. Cell toxicity was determined by LDH
release. Mean ± sem, n=3 experiments. ***, P<0.001; ANOVA, Tukey post-hoc pairwise
comparisons.
E WT or Grm5−/− cortical neurons were treated with 0 or 1 μM Aβo for 2 h. Toxicity was
determined by LDH release. Mean±sem, n=4 experiments. **, P<0.01; ANOVA, Tukey
post-hoc pairwise comparisons.
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Figure 7. mGluR5 Antagonist Reverses Learning and Memory Deficits in AD Mouse Models
A Spatial learning is plotted as the number of errors in finding a hidden platform in a radial
arm water maze at age 9 months. Mean±sem for vehicle treated C57BL/6, n=11; MTEP
treated C57BL/6, n=12; vehicle treated APP/PS1, n=10; MTEP treated APP/PS1, n=10.
Performance differed across the last 15 swims by genotype and treatment (two-way RM-
ANOVA APP/PS1, P<0.001; MTEP, P<0.001). There was an interaction between genotype
and treatment (two-way RM-ANOVA APP/PS1xMTEP P<0.001). By Tukey post-hoc
pairwise comparisons across trials, the vehicle-treated APP/PS1 group differed from each of
the other groups (P<0.001), while none of the other groups differed from each other
(P>0.05). For indicated trial blocks, the vehicle-treated APP/PS1 group differed from each
of the other groups (*P<0.05; **P<0.01; ***P<0.001), while none of the other groups
differed from each other (P>0.05).
B Time spent with a novel object for the same mice as A: vehicle C57BL/6, n=11; MTEP
C57BL/6, n=12; vehicle APP/PS1, n=9; MTEP APP/PS1, n=9. After being acclimated to an
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object, vehicle APP/PS1 mice showed no preference for a novel object (two tailed Student’s
t test P>0.05). The other 3 groups showed preference for a novel object (two tailed Student’s
t test P<0.001).
C Spatial learning is plotted as latency to find a hidden platform in a Morris water maze at
age 9 months in a cohort different from A. Mean±sem for untreated (naïve) C57BL/6, n=32;
MTEP treated C57BL/6, n=13; untreated APP/PS1, n=38; MTEP treated APP/PS1, n=17.
Performance differed across the last 16 swims by genotype and treatment (two-way RM-
ANOVA for APP/PS1, P<0.001; for MTEP, P<0.001). There was an interaction between
genotype and treatment (two-way RM-ANOVA, APP/PS1xMTEP P<0.001). By Tukey
post-hoc pairwise comparisons across trials, the vehicle-treated APP/PS1 group differed
from each of the other groups (***P<0.001), while none of the other groups differed from
each other (P>0.05). For specific trial blocks, the untreated APP/PS1 group differed from
each of the other groups (*P<0.05; ***P<0.001), while none of the other groups differed
from each other (P>0.05).
D Performance during a 60 sec probe trial, 24 h after learning, where time spent in the target
quadrant was measured. Random chance is 25%. Mean±sem for the groups in C. Target
quadrant time differed by genotype and treatment (two-way ANOVA APP/PS1, P<0.001;
MTEP, P<0.01). There was an interaction between genotype and treatment (ANOVA, APP/
PS1xMTEP P<0.001). By Tukey post-hoc, the untreated APP/PS1 group differed from
others (P<0.001), while none of the other groups differed from each other (P>0.05).
E WT and 3XTg mice of the same genetic background at 8–9 months of age were tested for
novel object recognition. WT mice show preference the novel object (two-tailed Student’s t
test P<0.05), but 3XTg mice show no preference (P>0.05). Mean±sem.
F The effect of MTEP administration on object recognition is tested in 3XTg mice at age 8
months. Mean±sem for vehicle 3XTg, n=12; MTEP 3XTg, n=8. Mice that received MTEP
had a significant preference for the novel object (two tailed Student’s t test P<0.01) while
vehicle 3XTg mice showed no preference (two-tailed Student’s t test P >0.05).
See also Fig. S6.
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Figure 8. Synaptic Markers Recover After 10-Day Treatment With mGluR5 Antagonist
WT and APP/PS1 mice at 10 months of age were treated with 15 mg/kg of MTEP, or saline,
by intraperitoneal injection twice a day for 10 days and then sacrificed for histological
analysis.
A–C The molecular layer of the dentate gyrus of the indicated groups was stained with anti-
PSD-95 antibody and imaged with a confocal microscope and a 60X objective lens. Scale
bar, 6 μm.
D Fractional area of immunoreactive puncta for PSD-95 from images as in A–C. P<0.05,
ANOVA with post-hoc pairwise LSD. Mean±sem, n=5 mice per group with 3 images per
mouse.
E Fractional area of immunoreactive puncta for synaptophysin. P < 0.05, ANOVA with
post-hoc pairwise LSD. Mean±sem, for n=5 mice per group with 3 images per animal.
F Ultrastructure of the molecular layer of the dentate gyrus from a vehicle APP/PS1 mouse.
Arrows point to synapses scored in G. Magnification is 20,500X. Scale bar, 1 μm.
G Synapses were counted in a 25 μm2 area in drug-treated and saline-treated samples.
P<0.05, two-tailed Student’s t test. Mean±sem, n=5 mice per group with 30 images per
mouse.
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